Source: Eur Respir J 2014; 43: 647-648
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Scott Jeremy A., Gauvreau Gail M., Grasemann Hartmut. Asymmetric dimethylarginine and asthma. Eur Respir J 2014; 43: 647-648

Member's Comments

No comment yet.

Related content which might interest you: Asymmetric dimethylarginine (ADMA) in EBC of asthmatic children Source: Annual Congress 2012 - Mechanisms and risk of childhood asthma and allergy Year: 2012 The role of asymmetric dimethylarginine (ADMA) in patients with asthma Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 Asymmetric dimethylarginine (ADMA) to monitor treatments of pulmonary hypertension Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Asymmetric dimethylarginine, a biomarker for the effects of drug therapy in pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: end-points and biomarkers Year: 2012 Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Asymmetric dimethylarginine and asthma: results from the Childhood Asthma Prevention Study Source: Eur Respir J 2013; 41: 1234-1237 Year: 2013 Increased alveolar epithelial expression of dimethylarginine dimethylaminohydrolase 2 in idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 823s Year: 2006 Asymmetric dimethylarginine (ADMA) in exhaled breath condensate (EBC) of children with cystic fibrosis (CF) Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Biomarkers in pulmonary hypertension Source: Eur Respir J 2008; 32: 503-512 Year: 2008 Attenuated expression and activity of dimethylarginine dimethylaminohydrolase may play a key role in monocrotaline-induced pulmonary hypertension by accumulation of endogenous NOS inhibitors in rats Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 The association between pulmonary arterial hypertension secondary to chronic lung disease and serum asymmetric dimethylarginine levels Source: Annual Congress 2012 - COPD comorbidities II Year: 2012 Hypoxia induced pulmonary hypertension – the role of dimethylarginine dimethylaminohydrolase 1 (DDAH-1) in acute and sustained hypoxic vasoconstriction Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Heat shock proteins, L-arginine, and asymmetric dimethylarginine levels in patients with obstructive sleep apnea syndrome Source: International Congress 2015 – Inflammation, biomarkers and hypoxia in sleep disordered breathing Year: 2015 Plasma asymmetric dimethylarginine (ADMA) in pediatric patients with cystic fibrosis (CF) Source: International Congress 2016 – Systemic biomarkers Year: 2016 Fractional exhaled nitric oxide is associated with more severe asthma Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 High levels of fractional exhaled nitric oxide (FeNO) in severe oral steroid-dependent asthma are associated with eosinophilia and atopy Source: Annual Congress 2009 - Airway inflammation and asthma control Year: 2009 Exhaled nitric oxide (FeNO) in relation to exacerbation of childhood asthma Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009 Asymmetric dimethylarginine concentration in patients with obstructive sleep apnea Source: International Congress 2015 – Inflammation, biomarkers and hypoxia in sleep disordered breathing Year: 2015 Early and late effect of acute bronchodilation on exhaled nitric oxide in asthma Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016 Exhaled nitric oxide, susceptibility and new-onset asthma in the Children’s Health Study Source: Eur Respir J 2011; 37: 523-531 Year: 2011